The withdrawal trials, read as designs rather than warnings
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Patient experience
Page 8 of 8 of this archive, newest first.
The advice is mostly reasonable. The certainty is not earned.
Grading six widely repeated claims against the studies actually behind them.
Grams per kilogram of what? The denominator problem in protein guidance
The practical difficulty is not knowing the target. It is meeting it on an appetite that has been pharmacologically reduced by half.
What happens when the drug is taken away: three randomised answers
The regain trajectories, arm by arm, with the estimands named.
The advice is mostly reasonable. The certainty is not earned.
A tour of the source literatures, with an assessment of how far each legitimately reaches.
What the older diet-and-exercise trials found in the hip
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
Why the bone question is harder than the muscle question
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
Two sessions a week, and the evidence behind the prescription
Mass and function are different endpoints and training affects them differently. Most coverage treats them as one.
Reading the semaglutide composition data without the press release
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
The one-quarter rule, and the paper that took it apart
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
What the older diet-and-exercise trials found in the hip
A plausible mechanism, a measurable change, and no outcome data. This is what an open question looks like.
Stepping down against stopping: two decisions treated as one
These agents produce no dependence and no withdrawal syndrome. What a taper would be for is therefore a real question rather than an obvious one.
A design note on withdrawal trials, and why the run-in matters
A withdrawal trial answers a narrower question than it appears to. This piece states which question.